PAM
CDTX

Panagora Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Panagora Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-24
Closed -$1K – 2828
2020
Q4 		$1K Sell
24
-885
-97% -$44K ﹤0.01% 2705
2020
Q3 		$52K Buy
909
+24
+3% +$1.7K ﹤0.01% 2003
2020
Q2 		$65K Buy
+885
New +$57.4K ﹤0.01% 1915

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Panagora Asset Management's CDTX Position: Q1 2021 in Review

Panagora Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2021, closing a stake of 24 shares — an estimated $1K sold.

Panagora Asset Management first reported a position in CDTX in Q2 2020 and held it in 3 quarters. The position peaked at $65K in Q2 2020. 62 funds tracked by Wall St. Rank hold CDTX as of Q1 2021.

  • Panagora Asset Management reported no remaining Cidara Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Panagora Asset Management sold 24 Cidara Therapeutics shares in Q1 2021, an estimated $1K.
  • Panagora Asset Management first reported a position in Cidara Therapeutics in Q2 2020 and held it in 3 quarters.
  • Panagora Asset Management's Cidara Therapeutics position peaked at $65K in Q2 2020.
  • 62 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2021.

Based on Panagora Asset Management's 13F filing for Q1 2021, filed 12 May 2021.